163 related articles for article (PubMed ID: 19622716)
21. Cost-effectiveness of a diabetes group education program delivered by health promoters with a guiding style in underserved communities in Cape Town, South Africa.
Mash R; Kroukamp R; Gaziano T; Levitt N
Patient Educ Couns; 2015 May; 98(5):622-6. PubMed ID: 25641665
[TBL] [Abstract][Full Text] [Related]
22. Long-term cost-effectiveness of collaborative care (vs usual care) for people with depression and comorbid diabetes or cardiovascular disease: a Markov model informed by the COINCIDE randomised controlled trial.
Camacho EM; Ntais D; Coventry P; Bower P; Lovell K; Chew-Graham C; Baguley C; Gask L; Dickens C; Davies LM
BMJ Open; 2016 Oct; 6(10):e012514. PubMed ID: 27855101
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness of a Short Message Service Intervention to Prevent Type 2 Diabetes from Impaired Glucose Tolerance.
Wong CK; Jiao FF; Siu SC; Fung CS; Fong DY; Wong KW; Yu EY; Lo YY; Lam CL
J Diabetes Res; 2016; 2016():1219581. PubMed ID: 26798647
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of Community Health Workers in controlling diabetes epidemic on the U.S.-Mexico border.
Ryabov I
Public Health; 2014 Jul; 128(7):636-42. PubMed ID: 24999158
[TBL] [Abstract][Full Text] [Related]
25. Estimating the Societal Benefits of THA After Accounting for Work Status and Productivity: A Markov Model Approach.
Koenig L; Zhang Q; Austin MS; Demiralp B; Fehring TK; Feng C; Mather RC; Nguyen JT; Saavoss A; Springer BD; Yates AJ
Clin Orthop Relat Res; 2016 Dec; 474(12):2645-2654. PubMed ID: 27699631
[TBL] [Abstract][Full Text] [Related]
26. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
27. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
[TBL] [Abstract][Full Text] [Related]
28. Economic Evaluation of Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force.
Li R; Qu S; Zhang P; Chattopadhyay S; Gregg EW; Albright A; Hopkins D; Pronk NP
Ann Intern Med; 2015 Sep; 163(6):452-60. PubMed ID: 26167962
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
Ericsson Å; Pollock RF; Hunt B; Valentine WJ
J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
[TBL] [Abstract][Full Text] [Related]
30. Estimating the Impact of Novel Digital Therapeutics in Type 2 Diabetes and Hypertension: Health Economic Analysis.
Nordyke RJ; Appelbaum K; Berman MA
J Med Internet Res; 2019 Oct; 21(10):e15814. PubMed ID: 31599740
[TBL] [Abstract][Full Text] [Related]
31. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
Gao L; Zhao FL; Li SC
Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of a National Telemedicine Diabetic Retinopathy Screening Program in Singapore.
Nguyen HV; Tan GS; Tapp RJ; Mital S; Ting DS; Wong HT; Tan CS; Laude A; Tai ES; Tan NC; Finkelstein EA; Wong TY; Lamoureux EL
Ophthalmology; 2016 Dec; 123(12):2571-2580. PubMed ID: 27726962
[TBL] [Abstract][Full Text] [Related]
33. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
Lee WC; Samyshkin Y; Langer J; Palmer JL
J Med Econ; 2012; 15 Suppl 2():28-37. PubMed ID: 22834986
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.
Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113
[TBL] [Abstract][Full Text] [Related]
35. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.
Pan F; Goh JW; Cutter G; Su W; Pleimes D; Wang C
Clin Ther; 2012 Sep; 34(9):1966-76. PubMed ID: 22906738
[TBL] [Abstract][Full Text] [Related]
36. A model-based economic evaluation of improved primary care management of patients with type 2 diabetes in Australia.
Haji Ali Afzali H; Gray J; Beilby J; Holton C; Karnon J
Appl Health Econ Health Policy; 2013 Dec; 11(6):661-70. PubMed ID: 24243516
[TBL] [Abstract][Full Text] [Related]
37. Cost-Effectiveness Analysis of a Skin Awareness Intervention for Early Detection of Skin Cancer Targeting Men Older Than 50 Years.
Gordon LG; Brynes J; Baade PD; Neale RE; Whiteman DC; Youl PH; Aitken JF; Janda M
Value Health; 2017 Apr; 20(4):593-601. PubMed ID: 28408001
[TBL] [Abstract][Full Text] [Related]
38. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
[TBL] [Abstract][Full Text] [Related]
39. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
[TBL] [Abstract][Full Text] [Related]
40. Costs and effects of a telephonic diabetes self-management support intervention using health educators.
Schechter CB; Walker EA; Ortega FM; Chamany S; Silver LD
J Diabetes Complications; 2016 Mar; 30(2):300-5. PubMed ID: 26750743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
